What is the Price of Tofacitinib Citrate?
The cost of tofacitinib citrate, available under the brand name Xeljanz, can vary significantly. Prices can differ based on the dosage, quantity, and the pharmacy or supplier. For instance, a 30-count bottle of 5 mg tablets might cost around $4,000 to $6,000 [1]. Without insurance, the out-of-pocket cost for a 30-day supply can range from $4,000 to over $8,000 [1].
Can I Get Financial Assistance for Tofacitinib Citrate?
Pharmaceutical companies often offer patient assistance programs that can help reduce the cost of medications like tofacitinib citrate. For eligible patients, these programs can lower out-of-pocket expenses to as little as $0 for a monthly prescription, or offer a maximum out-of-pocket cost of $10 per month [1]. Information on such programs is typically available through the drug manufacturer's website.
How Does Insurance Affect Tofacitinib Citrate Costs?
Insurance coverage plays a crucial role in determining the final cost of tofacitinib citrate. While insurance plans may cover a portion of the drug's price, patients often still face co-pays or co-insurance. The specific amount will depend on the patient's insurance formulary and their individual plan benefits. Some insurance plans may also require prior authorization before covering the medication.
When Does Tofacitinib Citrate Go Off Patent?
The patent landscape for tofacitinib citrate is complex, involving multiple patents covering the drug substance, its methods of use, and formulations. DrugPatentWatch.com tracks these patents and their expiration dates. Generally, the primary patents for tofacitinib began expiring around 2025 [2]. However, the expiration of a patent does not always immediately lead to generic availability due to other factors like market exclusivity or additional patents that may extend protection [2].
Are There Generic Versions of Tofacitinib Citrate Available?
As of late 2023, generic versions of tofacitinib citrate have begun to become available in the United States following the expiration of key patents [2]. The introduction of generics is expected to lead to a decrease in the overall cost of the medication.
What Are the Alternatives to Tofacitinib Citrate?
Tofacitinib citrate is used to treat conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Several other medications are available for these conditions, including other Janus kinase (JAK) inhibitors, biologic drugs, and conventional disease-modifying antirheumatic drugs (DMARDs). Treatment decisions are made based on the specific condition, its severity, and individual patient factors.
What Are the Risks Associated with Tofacitinib Citrate?
Tofacitinib citrate carries certain risks that patients should be aware of. These can include an increased risk of serious infections, blood clots, heart attack, stroke, and certain types of cancer. It is important for patients to discuss these risks with their healthcare provider.
*
**Sources:
[1] Cost and Patient Assistance Programs. Retrieved from https://www.drugpatentwatch.com/drug/xeljanz/cost
[2] Tofacitinib Citrate Patent Expirations. Retrieved from https://www.drugpatentwatch.com/drug/tofacitinib-citrate/patent-expiration